Heart failure patients with mid-range ejection fraction: clinical features and prognosis

Cover Page

Cite item

Abstract

Aim. To analyze clinical and echocardiographic characteristics and prognosis in patients with heart failure mid-range ejection fraction.

Methods. The study included 76 patients with stable heart failure I–IV functional class, with a mean age of 66.1±10.4 years. All patients were divided into 3 subgroups based on the left ventricular ejection fraction: the first group — heart failure patients with reduced ejection fraction (below 40%), 21.1%; the second group — patients with mid-range ejection fraction (from 40 to 49%), 23.7%; the third group — patients with preserved ejection fraction (>50%), 55.3%. The clinical characteristics of all groups were compared. The quality of life was assessed by the Minnesota Satisfaction Questionnaire (MSQ), the clinical condition was determined by using the clinical condition assessment scale (Russian “Shocks”). The prognosis was studied according to the onset of cardiovascular events one year after enrollment in the study. The endpoints were cardiovascular mortality, myocardial infarction (MI), stroke, hospitalization for acutely decompensated heart failure, thrombotic complications. Statistical analysis was performed by using IBM SPSS Statistics 20 software. Normal distribution of the data was determined by the Shapiro–Wilk test, nominal indicators were compared between groups by using chi-square tests, normally distributed quantitative indicators — by ANOVA. The Kruskal–Wallis test was performed to comparing data with non-normal distribution.

Results. Analysis showed that the most of clinical characteristics (etiological structure, age, gender, quality of life, results on the clinical condition assessment scale for patients with chronic heart failure and a 6-minute walk test, distribution by functional classes of heart failure) in patients with mid-range ejection fraction (HFmrEF) were similar to those in patients with reduced ejection fraction (HFrEF). At the same time, they significantly differed from the characteristics of patients with preserved ejection fraction (HFpEF). Echocardiographic data from patients with mid-range ejection fraction ranks in the middle compared to patients with reduced and preserved ejection fraction. In heart failure patients with mid-range ejection fraction, the incidence of adverse outcomes during the 1st year also was intermediate between heart failure patients with preserved ejection fraction and patients with reduced ejection fraction: for all cardiovascular events in the absence of significant differences (17.6; 10.8 and 18.8%, respectively), myocardial infarction (5,9; 0 and 6.2%), thrombotic complications (5.9; 5.4 and 6.2%). Heart failure patients with mid-range ejection fraction in comparison to patients with preserved ejection fraction and reduced ejection fraction had significantly lower cardiovascular mortality (0; 2.7 and 12.5%, p >0.05) and the number of hospitalization for acutely decompensated heart failure (0; 2,7 and 6.2%).

Conclusion. Clinical characteristics of heart failure patients with mid-range and heart failure patients with reduced ejection fraction are similar but significantly different from those in the group of patients with preserved ejection fraction; echocardiographic data in heart failure patients with mid-range ejection fraction is intermediate between those in patients with reduced ejection fraction and patients with preserved ejection fraction; the prognosis for all cardiovascular events did not differ significantly in the groups depending on the left ventricular ejection fraction.

About the authors

O V Bulashova

Kazan State Medical University

Email: hazova_elena@mail.ru
Russian Federation, Kazan, Russia

A A Nasybullina

Kazan State Medical University

Email: hazova_elena@mail.ru
Russian Federation, Kazan, Russia

E V Khazova

Kazan State Medical University

Author for correspondence.
Email: hazova_elena@mail.ru
Russian Federation, Kazan, Russia

V M Gazizyanova

Kazan State Medical University

Email: hazova_elena@mail.ru
Russian Federation, Kazan, Russia

V N Oslopov

Kazan State Medical University

Email: hazova_elena@mail.ru
Russian Federation, Kazan, Russia

References

  1. Mareev V.Yu., Fomin I.V., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L., Belenkov Yu.N., Vasyuk Yu.A., Galyavich A.S., Garganeeva A.A., Gendlin G.E., Gilyarevsky S.R., Glezer M.G., Drapkina O.M., Duplyakov D.V., Kobalava Zh.D., Koziolova N.A., Lopatin Yu.M., Mareev Yu.V., Moiseev V.S., Nedoshivin A.O., Perepech N.B., Sitnikova M.Yu., Ski­bitsky V.V., Tarlovskaya E.N, Chestnikova A.I., Shlyakhto E.V. Chronic heart failure (CHF). Zhurnal serdechnaya nedostatochnost'. 2017; 18 (1): 3–40. (In Russ.) doi: 10.18087/rhfj.2017.1.2346.
  2. Tsao C.W., Lyass A., Larson M.G., Cheng S., Lam C.S., Aragam J.R., Benjamin E.J., Vasan R.S. Prognosis of adults with borderline left ventricular ejection fraction. JACC Heart Fail. 2016; 4 (6): 502–510. doi: 10.1016/j.jchf.2016.03.003.
  3. Filippatos G., Khan S.S., Ambrosy A.P., Cleland G.F., Collins S.P., Lam S.P., Angermann C.E., Ertl G., Dahlstrom U., Hu D., Dickstein K., Perrone S.V., Ghadanfar M., Bermann G., Noe A., Schweizer A., Maier T., Gheorghiade M. International REgistry to assess medical Practice with Ongitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a glo­bal registry. Eur. J. Heart Fail. 2015; 17: 527–533. doi: 10.1002/ejhf.262.
  4. Solomon S.D., Anavekar N., Skali H., McMurray J.V., Swedberg K., Yusuf S., Granger C.B., Michelson E.L., Wang D., Pocock S., Pfeffer M.A. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005; 112: 3738–3744. doi: 10.1161/CIRCULATIONAHA.105.561423.
  5. Lam C.S., Solomon S.D. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur. J. Heart Fail. 2014; 16: 1049–1055. doi: 10.1002/ejhf.159.
  6. Kapoor J.R., Kapoor R., Ju C., Heidenreich P.A., Heidenreich P.A., Eapen Z.J., Hernandez A.F., Butler J., Yancy C.W., Fonarow C.C. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016; 4: 464–472. doi: 10.1016/j.jchf.2016.02.017.
  7. Lund L.H., Claggett B., Liu J. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum Eur. J. Heart Fail. 2018; 20: 1230–1239. doi: 10.1002/ejhf.1149.
  8. Rickenbacher P., Kaufmann B.A., Maeder M.T., Bern­heim A., Goetschalckx K., Pfister O., Pfisterer M., Brunner-La Rocca H.P. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur. J. Heart Fail. 2017; 19 (12): 1586–1596. doi: 10.1002/ejhf.798.
  9. Tsuji K., Sakata Y., Nochioka K., Takeshi Yamauchi M.M., Takeo Onose, Abe R., Oikawa T., Kasahara S., Sato M., Shiroto T., Takahashi J., Miyata S., Shimokawa H. Characterization of heart failure patients with mid-range left ventricular ejection fraction — a report from the CHART-2 study. Eur. J. Heart Fail. 2017; 19 (10): 1258–1269. doi: 10.1002/ejhf.807.
  10. Saikhan L.A., Hughes A.D., Chung W.S., Alsharqi M., Nihoyannopoulos P. Left atrial function in heart fai­lure with mid-range ejection fraction differs from that of heart failure with preserved ejection fraction: a 2D speckle-­tracking echocardiographic study. Eur. Heart J. Cardiovasc. Imaging. 2019; 20: 279–290. doi: 10.1093/ehjci/jey171.
  11. Solomon S.D., Claggett B., Lewis E.F., Desai A., Anand I., Sweitzer N.K., O'Meara E., Shah S.J., McKinlay S., Fleg J.L., Sopko G., Pitt B., Pfeffer M.A. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur. Heart J. 2016; 37 (5): 455–462. doi: 10.1093/eurheartj/ehv464.
  12. Bhambhani V., Kizer J.R., Lima A.C., van der Harst P., Bahrami H., Nayor M., de Filippi C.R., Enserro D., Blaha M.J., Cushman M., Wang T.J., Gansevoort R.T., Fox C.S., Gaggin H.K., Kop W.J., Liu K., Vasan R.S., Psaty B.M., Lee D.S., Brouwers F.P., Hillege H.L., Bartz T.M., Benjamin E.J., Chan C., Allison M., Gardin J.M., Januzzi J.L.Jr., Levy D., Herrington D.M., van Gilst W.H, Bertoni A.G., Larson M.G., de Boer R.A., Gottdiener J.S., Shah S.J., Ho J.E. Predictors and outcomes of heart failure with mid-range ejection fraction. Eur. J. Heart Fail. 2018; 20 (4): 651–659. doi: 10.1002/ejhf.1091.
  13. Tokmakova M.P., Skali H., Kenchaiah S., Braunwald E., Rouleau J.L., Packer M., Chertow G.M., Moyé L.A., Pfeffer M.A., Solomon S.D. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) stud. Circulation. 2004; 110: 3667–3673. doi: 10.1161/01.CIR.0000149806.01354.
  14. Shah K.S., Xu H., Matsouaka R.A., Bhatt D.L., Heidenreich P.A., Hernandez A.F., Devore A.D., Yancy C.W., Fonarow C.C. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J. Am. Coll. Cardiol. 2017; 70 (20): 2476–2486. doi: 10.1016/j.jacc.2017.08.074.
  15. Shavarova E.K., Babaeva L.A., Padaryan S.S., Lukina O.I., Milto A.S., Soseliya N.N. Chronic heart failure: clinical guidelines and real clinical practice. Rational pharmacotherapy in cardiology. 2016; 12 (6): 631–637. (In Russ.) doi: 10.20996/1819-6446-2016-12-6-631-637.

© 2021 Bulashova O.V., Nasybullina A.A., Khazova E.V., Gazizyanova V.M., Oslopov V.N.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies